Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma

NCT ID: NCT07168473

Last Updated: 2025-09-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 274 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-09
• Study Completion Date: 2026-09-18

Brief Summary

This study aims to compare the efficacy and safety of DW1807 and DW1807-R2 in patients with perennial allergic rhinitis and comorbid asthma. The primary objective is to demonstrate the superiority of DW1807 over DW1807-R2 in improving the reflective total nasal symptom score (rTNSS) after 4 weeks of treatment.

Conditions

Perennial Allergic Rhinitis Accompanied by Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Experimental

DW1807 \& DW1807-R2 placebo

Group Type: EXPERIMENTAL

Experimental

Intervention Type: DRUG

1. DW1807 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks

2. DW1807-R2 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks

Comparator

DW1807 placebo \& DW1807-R2

Group Type: ACTIVE_COMPARATOR

Comparator

Intervention Type: DRUG

1. DW1807 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks

2. DW1807-R2 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks

Interventions

Experimental

1. DW1807 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks

2. DW1807-R2 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks

Intervention Type: DRUG

Comparator

1. DW1807 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks

2. DW1807-R2 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

<Screening Visit>

1. Male or female adults aged 19 years or older.

2. Individuals with a confirmed history or treatment record of perennial allergic rhinitis for at least 2 years at the time of screening.

3. Individuals who have a positive result on an allergy skin prick test or serum allergen-specific IgE antibody test (e.g., MAST or ImmunoCAP) conducted within 1 year prior to screening, and have a documented history of allergy to at least one perennial allergen (e.g., house dust mites, cats, dogs, molds, etc.).

4. Individuals diagnosed with asthma classified as Step 2 to Step 4.

5. Individuals who voluntarily provide written informed consent to participate in this clinical trial.

<Randomization Visit>

1. Subjects who meet all of the following criteria based on self-assessed nasal symptom scores recorded in the subject diary during the 7-day run-in period.

① Performed nasal symptom evaluations twice daily (morning and evening) on at least 4 days during the run-in period.

② Had an average daily Reflective Total Nasal Symptom Score (rTNSS) of ≥6 (maximum score: 12).

2. Subjects with medication compliance of ≥80% during the 7-day run-in period.

Exclusion Criteria

1. Individuals diagnosed with non-allergic rhinitis of other causes.

2. Individuals with a documented acute exacerbation of asthma within 12 weeks prior to screening.

3. Individuals diagnosed with pulmonary diseases other than asthma.

4. Individuals diagnosed with the following types of sinusitis:

① Acute sinusitis within 4 weeks prior to screening.

② Clinically significant chronic sinusitis, as determined by the investigator.

5. Individuals with nasal polyps or other clinically significant nasal structural abnormalities.

6. Individuals who have undergone nasal or perinasal surgery within 12 weeks prior to screening.

7. Individuals with a documented upper respiratory tract infection (including the common cold) or systemic infection within 3 weeks prior to screening.

<B. Concomitant Medication Use>

1. Subjects who have initiated immunotherapy or changed the dosage within 4 weeks prior to the screening visit.

2. Subjects who are on chronic use of medications that, in the opinion of the investigator, may interfere with the assessment of the investigational product's efficacy (e.g., tricyclic antidepressants).

3. Subjects who are currently taking, or are expected to require during the study, any medications that are prohibited as per the protocol.

<C. Laboratory Criteria>

1. Subjects with serum AST (GOT) or ALT (GPT) levels > 2 × the upper limit of normal (ULN) based on screening test results.

2. Subjects with an estimated glomerular filtration rate (eGFR, calculated by CKD-EPI) < 30 mL/min/1.73 m² based on screening test results.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daewon Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Konkuk University Medical Center

Seoul, , South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Jong-in Son

Role: CONTACT

jonginson112@daewonpharm.com

+82-2-2204-7053

Other Identifiers

DW1807-301

Identifier Type: -

Identifier Source: org_study_id